Unidad de Información e Investigación Social y Sanitaria-UISYS, CSIC-Universidad de Valencia, España.
Rev Esp Cardiol. 2009 Dec;62(12):1404-17. doi: 10.1016/s1885-5857(09)73535-2.
The publication of research articles has increased considerably in recent years in all biomedical fields. The present study examines the position of Spanish quality research in cardiology in the European and world context, and its evolution during the 5-year period 2003-2007.
Using the Science Citation Index Expanded of Thomson Reuters as data source, we compared Spanish cardiovascular scientific production with that of the rest of countries in the European Union and of the most important countries worldwide, along with relative productivity as per number of inhabitants and Gross Domestic Product, and the number of citations in the journals of the <
Spain ranks sixth in the European Union and ninth worldwide in scientific production (tenth worldwide if only the journals of the first quartile of the CCS-JCR area are considered). As regards the number of citations received, Spain ranks seventh in the European Union and eleventh worldwide. In terms of relative productivity as per number of inhabitants and Gross Domestic Product, the Spanish ranking is less favorable (positions 15 and 18, respectively).
The ranking of Spanish cardiovascular research is similar to that of other biomedical fields, though its position is less favorable in relation to certain demographic and economical indicators. In order to maintain adequate investigational levels, it is necessary for the European governments and scientific societies to regard the promotion of high-quality cardiological research as a priority concern.
近年来,所有生物医学领域的研究文章出版数量都有了显著的增长。本研究旨在考察西班牙心脏病学领域高质量研究在欧洲和世界范围内的地位及其在 2003-2007 年这 5 年期间的演变。
本研究使用汤森路透的科学引文索引扩展版作为数据源,将西班牙心血管科学的产出与欧盟其他国家以及全球最重要国家的产出进行了比较,同时还比较了按人口和国内生产总值计算的相对生产力,以及期刊引文报告(CCS-JCR)的 <
西班牙在欧盟的科学产出中排名第六,在全球排名第九(如果只考虑 CCS-JCR 领域前四分之一期刊,则全球排名第十)。就收到的引文数量而言,西班牙在欧盟排名第七,在全球排名第十一。按人口和国内生产总值计算的相对生产力方面,西班牙的排名较低(分别为第 15 位和第 18 位)。
西班牙心血管研究的排名与其他生物医学领域相似,但与某些人口和经济指标相比,其地位不太有利。为了保持适当的研究水平,欧洲政府和科学协会有必要将促进高质量的心脏病学研究作为优先事项。